Get the Daily Brief
Latest Biotech News
Restructuring wave: Tessera cuts 35% as it pivots; Lyra halts development, shutters ops
Tessera Therapeutics announced permanent layoffs affecting roughly 35% of staff (about 90 employees) as it shifts focus to a gene‑editing collaboration with Regeneron and prioritizes an in‑vivo...
Scale and automation in CGT manufacturing — Asimov licenses LV Edge; Trenchant shows AutoCell data
Asimov licensed its LV Edge Packaging lentiviral production cell line to CDMO AGC Biologics, enabling single‑plasmid transfection workflows and reducing GMP plasmid costs, supply‑chain risk and...
Oncology diagnostics surge: Natera and Guardant report double‑digit growth in testing
Natera reported preliminary Q4 revenue driven by Signatera MRD test sales and processed over 923,600 tests in Q4, with oncology and MRD volumes up substantially year‑over‑year; the company guided...
Targeted therapies advance: FLOWERS shows osimertinib combinations; MOUNTAINEER confirms tucatinib benefit
The FLOWERS Phase 2 trial, published in Nature Communications, reported that osimertinib with or without savolitinib showed efficacy in EGFR‑mutant NSCLC patients with MET aberrations, providing...
AbbVie jumps into PD‑1xVEGF sweepstakes: $650M upfront, multibillion milestones loom
AbbVie struck an exclusive out‑of‑China license for RemeGen’s PD‑1×VEGF bispecific, paying $650 million up front with total deal value reported in the billions contingent on milestones. The...
Nvidia and Lilly double down on AI: $1B lab to accelerate drug discovery
Nvidia and Eli Lilly announced a joint investment — roughly $1 billion over five years — to build a San Francisco AI drug‑discovery lab that will pair Lilly’s biological and clinical data with...
Basecamp’s EDEN model... programmable gene insertion demonstrated at scale
Basecamp Research reported that its EDEN family of evolutionary AI models can design programmable gene‑insertion tools that place large therapeutic DNA sequences at precise genomic sites. In...
Big single‑cell dataset pact: Tahoe, Arc and Biohub pledge multimillion commitments
Tahoe Therapeutics, the Arc Institute, and Biohub announced a collaborative effort to generate an expansive single‑cell perturbation dataset—over 120 million cells across some 225,000 drug–patient...
Engineered skin as a living monitor: implanted graft signals inflammation
A Japanese research consortium led by Tokyo City University and the University of Tokyo described an implanted engineered skin "living sensor display" that fluoresces in response to internal...
FDA eases CGT controls: CBER details greater flexibility for manufacturing and CMC
The U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) published guidance outlining relaxed chemical, manufacturing and control (CMC) expectations for certain...
AutoCell promises dramatic CGT scale‑up: Trenchant shows prototype data
Trenchant Biosystems released internal and external validation data for its AutoCell automated cell‑and‑gene‑therapy (CGT) manufacturing prototype, reporting a reduction of vein‑to‑vein timelines...
Lyra halts LYR‑210 program and lays off staff: Board opts for strategic alternatives
Lyra Therapeutics announced it will suspend development of LYR‑210 for chronic rhinosinusitis and implement a workforce reduction that impacts its remaining employees. The board elected to cease...
CRISPR removes NOTCH2NLC repeats: New gene‑editing approach for NIID
Researchers reported a CRISPR/Cas9‑based strategy that precisely excises pathogenic GGC repeat expansions in NOTCH2NLC, a genetic cause of neuronal intranuclear inclusion disease (NIID). The work...
Sequencing firms push clinical reach: Oxford Nanopore gains IVDR CE/UKCA, PacBio inks ASO collaboration
Oxford Nanopore secured CE‑marking under the EU IVDR and UKCA marking for its GridIon Dx sequencer, positioning the platform for clinical deployment in Europe and the UK; the company also named...
Nvidia and Lilly invest $1 billion: AI drug lab to accelerate discovery
Nvidia and Eli Lilly announced a five-year, up-to-$1 billion co-investment to build an AI-focused drug discovery lab in San Francisco. The collaboration will place Nvidia engineers alongside Lilly...
Basecamp’s EDEN: AI models design programmable gene insertion
Basecamp Research published a preprint and reported that its evolutionary AI family, EDEN, can design tools for programmable gene insertion across thousands of human genomic sites. Using ~9.7...
AbbVie pays $650M — joins PD‑1×VEGF bispecific race with RemeGen deal
AbbVie agreed to license ex‑China rights to RemeGen’s PD‑1×VEGF bispecific (RC148), paying $650 million up front with potential milestones totaling several billion dollars. The deal, disclosed at...
Grail files for FDA premarket approval: Galleri commercial scale rises
Grail told investors at JP Morgan that it plans to submit its Galleri multi‑cancer early detection test to the FDA for premarket approval in Q1 2026 and projected full‑year 2025 revenue growth of...
10x Genomics to open CLIA lab: clinical collaborations target oncology and autoimmunity
10x Genomics announced three clinically focused collaborations and plans to open a CLIA‑certified lab in early 2027 to move single‑cell and spatial assays into regulated clinical workflows....
Tahoe, Arc Institute and Biohub fund massive virtual‑cell dataset: 120M+ single‑cell perturbations
Tahoe Therapeutics, the Arc Institute and the Chan‑Zuckerberg Biohub committed multimillion‑dollar resources to build a perturbation‑heavy single‑cell dataset intended to power virtual cell...